Cutaneous head and neck melanoma in OPTiM, a randomized phase 3 trial of talimogene laherparepvec versus granulocyte‐macrophage colony‐stimulating factor for the treatment of unresected stage IIIB/IIIC/IV melanoma

BACKGROUND: Cutaneous head and neck melanoma has poor outcomes and limited treatment options. In OPTiM, a phase 3 study in patients with unresectable stage IIIB/IIIC/IV melanoma, intralesional administration of the oncolytic virus talimogene laherparepvec improved durable response rate (DRR; continu...

Descripción completa

Detalles Bibliográficos
Autores principales: Andtbacka, Robert H. I., Agarwala, Sanjiv S., Ollila, David W., Hallmeyer, Sigrun, Milhem, Mohammed, Amatruda, Thomas, Nemunaitis, John J., Harrington, Kevin J., Chen, Lisa, Shilkrut, Mark, Ross, Merrick, Kaufman, Howard L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5129499/
https://www.ncbi.nlm.nih.gov/pubmed/27407058
http://dx.doi.org/10.1002/hed.24522

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5129499/
https://www.ncbi.nlm.nih.gov/pubmed/27407058
http://dx.doi.org/10.1002/hed.24522

Ejemplares similares